Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helong Zhang

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Signal Transduction and Targeted Therapy|October 15, 2021
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Pingyang Wang, Jie Zhang, et al.
Frontiers in Medicine|October 21, 2022
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort studyWeineng Feng, Yufeng Wang, Fengming Ran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
Chinese Clinical Oncology|November 9, 2020
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in ChinaYunpeng Yang, Nong Yang, Lin Wu, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Cancer Science|July 1, 2014
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancerYing Lin, Jianlun Liu, Xiaohua Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA|September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical TrialHuiyan Luo, Jin Lu, Yuxian Bai, et al.
Med (New York, N.Y.)|June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trialMingming He, Zhiqiang Wang, Jin Lu, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Signal Transduction and Targeted Therapy|October 15, 2021
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Pingyang Wang, Jie Zhang, et al.
Frontiers in Medicine|October 21, 2022
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort studyWeineng Feng, Yufeng Wang, Fengming Ran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
Chinese Clinical Oncology|November 9, 2020
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in ChinaYunpeng Yang, Nong Yang, Lin Wu, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Cancer Science|July 1, 2014
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancerYing Lin, Jianlun Liu, Xiaohua Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA|September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical TrialHuiyan Luo, Jin Lu, Yuxian Bai, et al.
Med (New York, N.Y.)|June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trialMingming He, Zhiqiang Wang, Jin Lu, et al.
Pageof 11